drugset / Trial / NCT03002779

A Study to Characterize the Absorption, Metabolism, and Excretion of 14C-JNJ-53718678 After a Single Oral Dose in Healthy Male Participants

NCT03002779

Phase 1 Completed 6 enrolled Janssen Research & Development, LLC
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to determine the routes of excretion for JNJ-53718678 and its metabolites, to explore the metabolic pathways of JNJ-53718678, and to determine the chemical structure of predominant metabolites in healthy adult male participants after a single oral dose of 500 milligram (mg) 14C-JNJ-53718678.

Timeline

Start
2017-01-26
Primary completion
2017-03-10
Completion
2017-03-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Rilematovir Other / unclassified 500 mg Oral

Indications

No indication recorded.